[144] Revolution Medicines, Inc. SEC Filing

Rhea-AI Filing Summary

Revolution Medicines (RVMD) has filed a Form 144 notice for the proposed sale of securities by an insider. The filing details a planned sale of 1,912 shares of common stock with an aggregate market value of $76,346.16 through broker Morgan Stanley Smith Barney LLC.

Key transaction details:

• Securities were acquired as Restricted Stock Units from the issuer on June 15, 2025
• Planned sale date: June 20, 2025
• Trading venue: NASDAQ
• Total shares outstanding: 186,267,544

The filing also discloses that the seller, Jeffrey Todd Cislini, previously sold 1,878 shares for gross proceeds of $74,800.74 on June 16, 2025. This Form 144 represents a routine insider transaction for restricted securities, with the seller affirming no knowledge of undisclosed material adverse information about the company.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	1912	76346.16	186267544	06/20/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	06/15/2025	Restricted Stock Units	Issuer			1912	06/15/2025	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
JEFFREY TODD CISLINI 700 Saginaw Drive Redwood City CA 94063	Common	06/16/2025	1878	74800.74

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

How many shares of RVMD stock are being sold according to the Form 144 filing from June 2025?

According to the Form 144 filing, 1,912 shares of RVMD common stock are proposed to be sold through Morgan Stanley Smith Barney LLC at an aggregate market value of $76,346.16.

What is the total number of outstanding shares for RVMD as reported in the June 2025 Form 144?

The Form 144 filing indicates that Revolution Medicines (RVMD) has 186,267,544 shares outstanding as of the filing date.

How did the RVMD insider acquire the shares being sold in the June 2025 Form 144?

The shares were acquired through Restricted Stock Units (RSUs) from the issuer on June 15, 2025. The filing indicates 1,912 shares were acquired through this RSU grant.

What previous sales has the RVMD insider made in the past 3 months before this Form 144?

According to the filing, Jeffrey Todd Cislini, located at 700 Saginaw Drive Redwood City CA 94063, previously sold 1,878 shares of RVMD common stock on June 16, 2025, with gross proceeds of $74,800.74.

When is the approximate date of sale for the RVMD shares listed in this Form 144?

The Form 144 filing indicates that the approximate date of sale for the 1,912 RVMD shares is June 20, 2025, and they will be sold on the NASDAQ exchange.